Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Home
Juno Therapeutics
Juno Therapeutics
Activities:
Research & Development
Trending Articles
Novartis to acquire clinical-stage biopharma company, Anthos Therapeutics
Through the deal, Novartis will acquire Anthos' lead asset abelacimab, a fully human monoclonal anticoagulant designed to prevent stroke and systemic embolism in patients with...
Neopac becomes the first tube manufacturer to pass the RecyClass EN 15343 audit
The EN 15343 certification regulates the use of recycled materials in plastic packaging, ensuring products are traceable, sustainable and of a high quality
Ariceum Therapeutics' radiopharmaceutical SCLC therapeutic receives FDA Orphan Drug Designation
The therapeutic candidate will enter into Phase I/II clinical trials in Q1 of 2025, and has shown significant promise in treating aggressive cancers such as SCLC in preclinical...
You need to be a subscriber to read this article.
Click here
to find out more.
Beginnings, endings and transitions: Janus and the business of pharmaceuticals
Dr Kevin Robinson recently caught up with pharmaceutical industry experts to review what they considered to be the sector’s key challenges and achievements in 2024 and what...
L.B. Bohle to unveil a "first of its kind" at INTERPHEX NYC
Ideal for R&D and small-scale through commercial production stages, company’s newly enhanced QbCon1 combines three continuous processes: raw material dosing, twin-screw wet...
Upcoming event
Pharma Packaging and Labelling Forum
5–6 March 2025 | Conference | San Diego, US
See all
Related Content
Media
Celgene set to become leader in CAR-T space
According to GlobalData, a data and analytics company, Celgene’s acquisition of Juno Therapeutics puts the company in a good position to be a frontrunner in the chimeric antigen receptor-T cell space
Research & Development
Juno Therapeutics and WuXi AppTec announce new company to develop novel cell-based cancer immunotherapies in China
JW Biotechnology will Leverage Juno's immuno-oncology expertise and assets and WuXi AppTec's R&D and manufacturing platform
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Finance
Juno Therapeutics acquires German biotech Stage Cell Therapeutics for US$81m
Gaining access to transformative cell selection and activation capabilities
Research & Development
US cancer research centres launch biotech start-up
Juno Therapeutics will have US$120m initial investment and develop cancer immunotherapy products
Subscribe now